Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].
Indrák K, Hubácek J, Mayer J, Voglová J, Jarosová M, Krahulová M, Malý J, Faber E, Penka M, Kmonícek M, Jebavý L, Szotkowski T, Knotková R, Hlusí A, Zapletalová J. Indrák K, et al. Among authors: szotkowski t. Vnitr Lek. 2001 Sep;47 Suppl 1:48-56. Vnitr Lek. 2001. PMID: 11693063 Clinical Trial. Czech.
[Prognostic significance of cytogenetic changes in patients with acute myeloid leukemia (AML). (Analysis of results in 105 patients treated at the Hemato-oncology Clinic of the University Hospital in Olomouc from 1997 to 2000].
Jarosová M, Indrák K, Holzerová M, Hubácek J, Faber E, Papajík T, Raida L, Szotkowski T, Knotková R, Hlusí T, Jedlicková K, Pikalová Z, Sulovská I. Jarosová M, et al. Among authors: szotkowski t. Vnitr Lek. 2001 Sep;47 Suppl 1:8-14. Vnitr Lek. 2001. PMID: 11693065 Czech.
[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M, Doubek M, Schwarz J, Pytlík R, Dulícek P, Kissová J, Hlusí A, Vozobulová V, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Schutzová M, Hadacová I, Hochová I, Voglová J, Siroký O, Belada D, Lhot'anová T, Bubeník B, Vránová M, Micaníková M, Dusek L. Penka M, et al. Among authors: szotkowski t. Vnitr Lek. 2006 May;52(5):498-503. Vnitr Lek. 2006. PMID: 16771099 Czech.
[Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
Penka M, Schwarz J, Pavlík T, Pytlík R, Doubek M, Dulícek P, Pospísilová D, Kissová J, Hlusí A, Schützová M, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Lhotanová T, Bubeník B, Zapletal O, Vránová M, Micaníková M, Dusek L. Penka M, et al. Among authors: szotkowski t. Vnitr Lek. 2007 Jun;53(6):653-61. Vnitr Lek. 2007. PMID: 17702125 Czech.
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine].
Penka M, Schwarz J, Pavlík T, Pytiĺk R, Doubek M, Dulícek P, Kissová J, Hlusi A, Schutzová M, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Dusek L. Penka M, et al. Among authors: szotkowski t. Vnitr Lek. 2008 Jul-Aug;54(7-8):775-82. Vnitr Lek. 2008. PMID: 18780577 Czech.
52 results